John Chow, MD
Endocrinology, Diabetes & Metabolism · Edina, MNNPI 1851365985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations.
Across 181 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$364
- Amgen$236
- Insulet Corporation$209
- AstraZeneca$172
- Dexcom, Inc.$157
- Antares Pharma, Inc.$149
- plus $2K from 35 others
What the payments were for
- Food & beverage$2,89298%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 19 | $364 |
| Amgen(2 entities) | 16 | $236 |
| Insulet Corporation | 12 | $209 |
| AstraZeneca(2 entities) | 10 | $172 |
| Dexcom, Inc. | 11 | $157 |
| Antares Pharma, Inc. | 11 | $149 |
| Abbott | 8 | $142 |
| Mannkind Corporation | 4 | $118 |
| BETA Bionics, Inc. | 9 | $116 |
| Esperion Therapeutics, Inc. | 6 | $88 |
| Bayer | 5 | $80 |
| Recordati_rare_diseases_inc. | 4 | $80 |
| Novo Nordisk | 6 | $74 |
| Cequr Corporation | 3 | $71 |
| Radius Health, Inc. | 5 | $68 |
| Ipsen Biopharmaceuticals, Inc | 4 | $60 |
| Lifescan, Inc. | 4 | $54 |
| Boehringer Ingelheim | 3 | $51 |
| Ascensia Diabetes Care US Inc. | 3 | $50 |
| Corcept Therapeutics | 2 | $48 |
| Intuity Medical Inc | 3 | $47 |
| Novartis | 3 | $46 |
| Kyowa Kirin, Inc. | 3 | $43 |
| Chiesi USA, Inc. | 2 | $37 |
| Merck | 3 | $37 |
| Tandem Diabetes Care, Inc. | 2 | $37 |
| Pfizer | 2 | $35 |
| Amryt Pharma Holdings Ltd | 2 | $34 |
| Valeritas, Inc. | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Companion Medical, Inc. | 2 | $27 |
| Lilly USA, LLC | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Senseonics, Incorporated | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$2,952 in reported general payments places this provider in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 214 | $386,860 |
| MounjaroTirzepatide | 205 | $308,890 |
| JardianceEmpagliflozin | 135 | $177,055 |
| TrulicityDulaglutide | 77 | $109,631 |
| FarxigaDapagliflozin Propanediol | 61 | $91,581 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 60 | $83,388 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $43,921 |
| Humalog Kwikpen U-100Insulin Lispro | 120 | $40,991 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $36,693 |
| SynthroidLevothyroxine Sodium | 202 | $26,019 |
| Testosterone | 77 | $22,597 |
| Levothyroxine Sodium | 1,170 | $21,289 |
| HumalogInsulin Lispro | 79 | $20,858 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 151 | $20,714 |
| Norditropin FlexproSomatropin | 11 | $16,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $20 | $440,551373 claims |
| Novo NordiskOzempic, Novolog | $74 | $399,326255 claims |
| Boehringer IngelheimJardiance | $51 | $177,055135 claims |
| AstraZenecaFarxiga | $172 | $91,58161 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $13 | $16,74937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Edina
- Thomas LaedtkeEdina$39K
- Elizabeth HaglindEdina$3K
- Sarah Bou MalhamEdina$549
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.